Clinical Trial Search

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Drugs (SVR12 Planned) — 72.8; 74.3 percentage of…

Primary: VAS for Lumbar Pain in 3 Months — 2.63; 4.53 units on a scale — p=0.05

Primary: Change From Baseline in Days Homeless Out of the Previous 6 Months as Measured at 25 Weeks — 6.50; 9.85 days

Primary: Time From Randomization to the Occurrence of a Bipolar Event (TOBE) — 50; 155; 120; 163 Days — p=0.0717

Primary: Pain Intensity — 0.3; 0.4 units on a scale

Primary: Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52 — -0.67; -0.79 Percentage of HbA1c in the blood — p=0.0086

Primary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 79.5; 50 Percentage of participants…

Primary: Percentage of Participants Maintaining a Psoriasis Area and Severity Index 75 (PASI75) Response During the Double-Blind Treatment Withdrawal Period (Period B) — 90.3…

Primary: Number of Participants Who Attained a Change of -30% or Greater in the VAS Score — 23; 4 participants — p=<0.00005

Primary: The Primary Outcome Measure is the Number of Subjects in Each Group Who Are Able to Pass the DriveABLE On-Road Test at Month 12 (Endpoint). — 13; 10; 13; 9 participants

Primary: Percentage of Participants Achieving an Overall Hematologic Response by Subpopulation and Total Population — 77.4; 55.0; 9.5; 59.2 percentage of participants

Primary: Number of Participants Who Seroconvert to Human Papillomavirus (HPV) Type 6 — 147; 1 Participants

Primary: Insertion Time — 26; 18 seconds

Primary: Percent Change in Brain Response Measured by Functional Magnetic Resonance Imaging (fMRI) — -.92; .07 percent change in BOLD signal — p=.001

Primary: Infection for P. Vivax — 11; 11; 9 days